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Abstract 
Constitutively activated signal transducer and activator of transcription 3 (STAT3) factor is an 
important therapeutic target in head and neck cancer (HNC). Despite early promising results, a 
reliable systemic delivery system for STAT3- targeted oligonucleotide (ODN) drugs is still needed 
for future clinical translation of anti-STAT3 therapies. We engineered and tested a novel ODN 
duplex/gold nanoparticle (AuNP)-based system carrying a therapeutic STAT3 decoy (STAT3d) 
payload. This strategy is two-pronged because of the additive STAT3 antagonism and 
radiosensitizing properties of AuNP. The specificity to head and neck cancer cell surface was 
imparted by using a nucleolin aptamer (NUAP) that was linked to AuNP for taking the advantage of 
an aberrant presentation of a nuclear protein nucleolin on the cell surface. STAT3d and nucleolin 
aptamer constructs were independently linked to AuNPs via Au-S bonds. The synthesized AuNP 
constructs (AuNP-NUAP-STAT3d) exhibited internalization in cells that was quantified by using 
radiolabeled STAT3d. AuNP-NUAP-STAT3d showed radiosensitizing effect in human HNC FaDu 
cell culture experiments that resulted in an increase of cell DNA damage as determined by 
measuring γ-H2AX phosphorylation levels by flow cytometry. The radiosensitization study also 
demonstrated that AuNP-NUAP-STAT3d as well as STAT3d alone resulted in the efficient 
inhibition of A431 cell proliferation. While FaDu cells did not show instant proliferation inhibition 
after incubating with AuNP-NUAP-STAT3d, the cell DNA damage in these cells showed nearly a 
50% increase in AuNP-NUAP-STAT3d group after treating with radiation. Compared with 
anti-EGFR humanized antibody (Cetuximab), AuNP-NUAP-STAT3d system had an overall stronger 
radiosensitization effect in both A431 and FaDu cells. 
Key words: oligonucleotide, aptamer, gold nanoparticle, confocal microscopy, STAT3. 
Introduction 
Despite recent progress in decreasing mortality 
rates, head and neck cancers, which constitute 2% of 
all cancers in women and 4% in men, an estimated 
49,670 new cases of cancer of the oral cavity and 
pharynx (throat) (oral, lip and oropharyngeal cancer 
accounts for up to 75% of all HNC) are expected in 
2017 in the USA [1]. The progression of HNC had 
been linked to constitutive activation of JAK/STAT3 
axis via IGF and EGFR signaling that has been 
implicated in promoting resistance to apoptosis and 
immune evasion/suppression [2]. Signal transducer 
and activator of transcription 3 (STAT3) is a 
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transcription factor that is constitutively activated in a 
variety of human malignancies, including prostate, 
lung, brain, breast, and squamous cell carcinomas and 
skin cancer [3, 4]. Constitutively activated STAT3 is an 
early event in head and neck carcinogenesis that 
contributes to the loss of growth control by an 
anti-apoptotic mechanism [5]. 
STAT3 is a critical regulating element of 
EGFR-STAT3-BclXL signaling axis, aberrantly 
activated in majority of HNC [6]. In the past, blocking 
of STAT3 activation with STAT3 decoys (STAT3d) has 
been actively explored as a potential strategy for 
attenuating resistance to chemo-, radio- and other 
therapies of HNC [2]. STAT3 decoy (STAT3d) is a 
therapeutic oligonucleotide duplex that potentially 
could be used to decrease STAT3 activation. STAT3d 
has shown selective binding for STAT3 protein and 
has been shown to inhibit the proliferation and 
survival of HNC [7] and the growth of HNC xenograft 
tumors in vivo [8]. Current limitation in the 
translation of STAT3d into clinical use is insufficient 
stability and a lack of specificity to HNC surface 
resulting in a low efficacy of systemic delivery to head 
and neck tumors. Gold nanoparticles for years were 
considered attractive as delivery agents and 
radiosensitizers due to past clinical use, the ease of 
surface modification and conjugation, high Z (Z=79) 
of gold with strong absorption of X-ray as well as the 
subsequent emission of secondary electrons (such as 
Auger electrons, photoelectrons and Compton 
electrons) and enhanced localized radiation dosage 
[9-16]. We hypothesized that AuNPs due to a very 
large cumulative surface area are capable of 
delivering high numbers of STAT3d to tissues and 
into cells, and that the accumulation of AuNPs in 
cancer cells or tumor can enhance radiation treatment 
resulting in additive therapeutic effect.  
Cancer-targeted therapies in most cases rely on 
cell surface receptors to direct anticancer agents to 
tumors [17, 18]. Therefore, we decided to explore 
known aberrant expression of nucleolin for enhancing 
targeted therapy to head and neck cancer cells which 
frequently display this protein on the surface [19, 20]. 
We linked nucleolin aptamer to AuNP-STAT3d 
delivery system. Nucleolin aptamer is known to have 
high affinity to nucleolin, a Bcl-2 mRNA binding 
protein involved in cell proliferation [21, 22]. The 
overexpression of nucleolin on the cell surface and in 
the cytoplasm of exponentially growing cells suggests 
that this protein not only can shuttle molecules 
between the nucleus and the cytoplasm, but also can 
function as a receptor for cell-type independent 
targeted cancer treatment.  
In this study, we report on a novel dual 
theranostic strategy in which the potential of AuNP is 
explored for both as a vehicle for STAT3d delivery via 
cell-surface nucleolin and simultaneously as a 
radiosensitizer for combinational therapy of 
head-and-neck cancer.  
Materials and Methods 
Cell culture 
Human cervical carcinoma HeLa cell line 
(American Type Culture Collection, ATCC, CCL-2) 
was maintained in DMEM (Gibco™ DMEM, Thermo 
Fisher Scientific) supplemented with 10% fetal bovine 
serum, FBS (Thermo Fisher Scientific). The human 
epithelial cell line MCF-10A (ATCC, CRL-10317) was 
maintained in DMEM/F12 medium supplemented 
with 10% horse serum (Thermo Fisher Scientific), 20 
ng/mL epidermal growth factor (Sigma-Aldrich), 0.5 
mg/mL hydrocortisone (Sigma-Aldrich), 100ng/mL 
cholera toxin (Sigma-Aldrich), and 10µg/mL insulin 
(Sigma-Aldrich). Ovarian carcinoma cell line 
OVCAR-3 (ATCC, HTB-161) was maintained in 
RPMI-1640 medium (Gibco) supplemented with 20% 
FBS and 10 µg/mL insulin (Sigma Aldrich). Human 
epithelial carcinoma cell line A431 (ATCC, CRL-1555) 
was maintained in DMEM supplemented with 10% 
FBS. Human pharyngeal squamous cell carcinoma 
line FaDu (ATCC, HTB-43) was maintained in EMEM 
(Thermo Fisher Scientific) supplemented with 10% 
FBS. 
Aptamers 
Nucleolin aptamer and control aptamer were 
synthesized by TriLink BioTechnologies (San Diego, 
CA). Nucleolin aptamer (NUAP) sequence [23] was 
5’-(NH2-C6) GGT GGT GGT GGT TGT GGT GGT 
GGT GGT TTT TT (C6-S-S-C6)-3’. Control aptamer 
(CTAP) sequence: 5’-(NH2-C6) CCT CCT CCT CCT 
TCT CCT CCT CCT CCT TTT TT (C6-S-S-C6)-3’. 
STAT3 decoy and mutant control decoy 
Sense and antisense ODN strands of STAT3 
decoy and mutant decoy oligonucleotides were 
synthesized by GenScript (Piscataway, NJ). The 
STAT3 decoy sequence [7] was: 5’-(NH2-C6) C*A*T* 
TTC CCG TAA ATC TTT (C6-S-S-C6)-3’, 3’-(NH2-C7) 
GT*A* A*AG GGC ATT T*A*G*-5’ and the mutant 
control decoy (COTRd) sequence was: 5’-(NH2-C6) 
C*A*T* TTC CCT TAA ATC TTT (C6-S-S-C6)-3’, 
3’-(NH2-C7) GT*A* A*AG GGA ATT T*A*G*-5’, 
where * stands for phosphorothioate bond. Decoy 
duplexes were prepared by mixing equimolar 
amounts of the corresponding complementary ODNs 
in 25 mM Hepes, 1 mM MgCl2, 50 mM NaCl, pH 7.4, 
heating the solutions to 95°C for 5 min and cooling 
down to room temperature. 
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Conjugation of STAT3 decoy strand with 
NHS-MAG3 
5 µL of 100mM solution of NHS-MAG3 in dry 
DMF was added to 100 µL 500 µM STAT3 decoy sense 
strand (STAN, has an amino group on 5’-end) in 0.1 M 
HEPES, pH 8.0. After incubating for 30-60 min at RT, 
STAN-MAG3-conjugate was purified by using a P6 
column (Bio-Rad) following the manufacturer’s 
instructions. Duplex containing STAN-MAG3 was 
prepared as described above. 
Preparation of AuNP-ODNs 
The reduction of 3’-disulfide was performed by 
adding tris-(2-carboxyethyl)phosphine hydrochloride 
(Sigma-Aldrich) at a final concentration of 50 mM 
followed by an incubation for 15-20 min at room 
temperature. The ODN was purified using a P6 
column equilibrated with 0.1M MES buffer pH 6. The 
thiolated ODN solution was added to 10 mL of 2 nM 
solution of AuNP (synthesized as described before 
[24]) as the final molar ratio was 1:200 (AuNP:ODN) 
and left overnight to form the nanoconstruct 
(AuNP-ODN). To increase the surface concentration 
of aptamers on AuNP, we diluted the incubation 
mixture with 2.5 mL of 0.5 M NaCl twice, with a 4 h 
interval in between. AuNP-ODN conjugate was 
purified by centrifugation at 16,000xg for 15 min and 
washing the AuNP-ODN conjugate twice with 10 mM 
sodium phosphate buffer, 0.1M NaCl, pH 7.0. 
Hydrodynamic diameters and zeta potentials of 
AuNP constructs were characterized using LALLS 
(Zetasizer Nano, Malvern Instruments Inc., 
Westborough, MA). The loading of ODN onto AuNP 
was calculated by measuring fluorescence intensities 
of free fluorescent ODN and the total added 
fluorescent ODN. 
Radiolabeling of MAG3-STAT3 decoy and 
MAG3-STAT3 decoy-AuNP 
Radiolabeling of various MAG3 conjugated 
preparations was performed as described [25]. Forty 
µL 0.25 M ammonium acetate were added to 5-10 µg 
of MAG3-STAT3d or to 2-5 µg of AuNP conjugates 
followed by an addition of sodium tartrate (50mg/ml) 
in sodium bicarbonate/ammonium acetate/ 
ammonium hydroxide buffer (pH 9.2). The final 
concentration of tartrate was 7 µg/mL. After addition 
of 9.25–37 MBq of 99mTc-pertechnetate, 2-5 µL of a 
fresh solution of SnCl2·2H2O (4 mg/mL in 10 mM 
HCl) were added. The labeling mixture was incubated 
at room temperature for 30–60 min. The 99mTc-labeled 
MAG3 AuNP was purified by gel filtration. 
Radiolabeling efficiency was between 70-80% before 
purification. After the purification radiochemical 
purity always exceeded 95% as determined by 
size-exclusion HPLC (Superdex 75, GE Healthcare 
Life Sciences), by instant thin-layer chromatography 
(ITLC) with acetone as the solvent (ITLC-SG; 
Gelman), or by paper chromatography (Whatman no. 
1; VWR) with saline as mobile phase.  
Immunofluorescence 
Cells were fixed for 15 min in 4% 
paraformaldehyde in PBS. After several washes in 
PBS, the fixed cells were blocked with 5% BSA in PBS 
for 1-2h. The cells were stained either with or without 
permeabilization with 0.1% Triton X-100/PBS using 
an overnight incubation with the anti-nucleolin 
antibody (rabbit polyclonal, ab22758, AbCam, 400x 
dilution with 5% BSA/PBS). The cells were further 
incubated for 2 h with the secondary anti-rabbit 
IgG(H+L)-FITC conjugate. Cells were washed 
mounted in anti-fade medium (Vector Labs) 
containing DAPI. The slides were examined using a 
Leica TCS SP8 confocal microscope (Leica 
Microsystems, Buffalo Gove, IL) using a 63x/1.4NA 
lens and 95.6 µm pinhole (at 1AU, λem=580 nm) 
resulting in an approximate optical section thickness 
of dz = 1.4 µm.  
Western blot analysis 
Heat-denatured DTT-reduced cell protein 
samples of A431 and FaDu cell lysate isolated by 
using a subcellular protein fractionation kit (Thermo 
Fisher Scientific) as well as HeLa whole cell lysate, 
positive control (Santa Cruz Biotechnology), were 
resolved by electrophoresis on 4-20% TGX gradient 
Tris/Tricine/SDS precast gels (Bio-Rad, Hercules 
CA). The gels were transferred to PVDF 
(polyvinylidene difluoride membranes, Bio-Rad), the 
membranes were blocked with 5% nonfat dried milk, 
0.1% Tween 20 in TBS for 2h at room temperature and 
then incubated with anti-STAT3 (sc-482, Santa Cruz 
Biotechnology, Dallas, TX) or anti-nucleolin (see 
above) primary antibodies (diluted 1:500) at 4°C 
overnight. The bands were visualized using alkaline 
phosphatase- conjugated anti-rabbit antibody (A3687 
Sigma-Aldrich) using BCIP/NBT (5-bromo-4-chloro- 
3-indolyl phosphate /Nitroblue Tetrazolium) 
substrate solution (Roche Diagnostics). The 
membrane was imaged using UVP EpiChemi system. 
Cell Viability Assay 
Cells were plated in 96-well plates in triplicate 
(60-70% confluence in 24h after plating). Cells were 
incubated with AuNP-ODNs (20 to 100 nM, 0.1 mL) in 
Opti-MEM medium for 1 d at 37°C/5%CO2. In control 
wells AuNP-ODN was replaced with 
phosphate-buffered saline (PBS). After 1 d the 
medium was replaced with 100 µL of fresh medium 
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and 10 µL of WST-1 reagent (Roche Molecular 
Biochemical) was added to each well and the plates 
were incubated for 0.5-3h at 37°C. The absorbance 
was measured using a SpectraMax M5 microplate 
reader (Molecular Devices) at 450 nm. Cytotoxicity 
was determined by comparing the absorbance values 
to that of controls. 
ODN and AuNP-ODN constructs cell 
internalization study 
Cells were seeded in either 12-well plate or 
96-well plates in respective media and incubated at 
37°C with 5% CO2. Next day the media were removed 
and test amounts of the aptamer (NUAP or CTAP), 
AuNP-ODNs, AuNP-NUAP-STAT3d or AuNP- 
CTAP-STAT3d with fluorescent tag or radiolabeled 
by 99mTc in Opti-MEM medium were added for 
various time periods. After incubation, the media 
containing unbound fraction was removed and cells 
were washed twice with PBS. For dissociating the 
surface bound AuNP-ODN nanoconstructs, glycine 
buffer (0.1M, pH 2.8) was added and the plate 
incubated for 5 min. After transferring to test tubes 
the cells were treated once in glycine buffer, glycine 
buffer fractions and PBS fractions were pooled to 
determine the surface-bound fraction. Following 
glycine buffer treatment the surface fractions were 
lysed with 0.2M NaOH/0.1% SDS and the lysates 
were counted using a Packard Gamma Counter. 
ODND and AuNP-ODN constructs were added to the 
cells at the final concentration as 0.5 µM. The 
fluorescence intensity of each lysis solution was 
measured by using Odyssey imager (Li-Cor 
Biotechnology, Lincoln NE) followed by ImageJ 
analysis [26]. 
AuNP-NUAP-STAT3d cell uptake 
measurements 
Cells were seeded on coverslips in 12-well plates 
and used at 60-70% confluence. STAT3d (0.5 µM) and 
AuNP-NUAP-STAT3d construct (5 nM AuNP with 
linked NUAP: 110 nM, STAT3d: 88 nM) with one 
strand of STAT3d labeled with Alexa Fluor 568 in 
Opti-MEM were added to the cells and incubated 
overnight. The cells were washed three times with 
PBS and fixed for 15 min in 4% formaldehyde. Cell 
plasma membrane was stained by using anti-EGFR 
(Cetuximab) - Alexa Fluor 488 conjugate. The cells 
were mounted in Vectashield anti-fading mounting 
medium with DAPI (Vector Laboratories, 
Burlingame, CA) and sealed on slides. The slides were 
examined using a Leica TCS SP8 confocal microscope 
(Leica Microsystems, Buffalo Gove, IL) using a 
63x/1.4NA lens and 95.6 µm pinhole (at 1AU, λem=580 
nm) resulting in an approximate optical section 
thickness of dz = 1.4 µm. All images were taken under 
the same condition. Three to four fields were imaged 
in three channels and saved as tiff files which were 
analyzed by using ImageJ software as follows: first, 
cell boundaries were outlined individually with ROI 
drawn by following green channel fluorescence signal 
representing anti-EGFR (Cetuximab) - Alexa Fluor 488 
conjugate binding to cell membrane. The ROIs 
derived from the outlines of individual cells were 
then pasted onto the “red” channel images and the 
corresponding signals in the “red” (Alexa Fluor 568) 
channel were calculated. Fluorescence intensities 
were determined for 30-40 cells in three to four fields 
of the view and the uptake of Alexa Fluor 568-labeld 
STAT3d was expressed as mean intensity/cell.  
Cell culture radiosensitization experiments 
FaDu and A431 cells at 60-70% confluence in 
6-well plates were treated with 20μg/ml Cetuximab 
(Merck), STAT3d (0.5 μM) and AuNP-NUAP-STAT3d 
nanoconstruct (88 nM STAT3d, 5.2 nM AuNP) for 20 
h. After the incubation the cells were mock-irradiated 
or irradiated with a single dose of 4Gy using a clinical 
linear accelerator unit (Philips, Department of 
Radiation Oncology, UMASS-Memorial Hospital, 
Worcester MA). The cells were washed with PBS 
twice, trypsinized, fixed and dispersed in 10% 
FBS/PBS. To quantify radiation therapy-induced 
DNA damage to cells, the cells were permeabilized 
and stained with FITC-labeled rabbit polyclonal 
antibodies against γ-H2AX (antiphospho-H2AX 
[Ser139]; Upstate Biotechnology, Lake Placid, NY) to 
determine the level of DNA damage in viable cells 
[27]. γ-H2AX levels were measured and analyzed by 
flow cytometry [13, 28, 29]. Non-specific IgG-FITC 
conjugate was used as negative control. 
Statistical analysis 
P values were calculated by using ordinary 2way 
ANOVA analysis (alpha=0.05), Prism 7.0, GraphPad 
Software Inc.  
Results 
Nucleolin aptamer and STAT3 decoy and 
AuNP delivery system 
Synthetic nucleolin aptamer [23] and the control 
aptamer (CTAP) with the guanines replaced with 
cytosines were used in this study; STAT3 decoy [7] 
was derived from the conserved hSIE genomic 
element found in the c-fos gene promoter and was 
composed of a duplex ODN with phosphorothioate 
modifications of the three 5’- and 3’- terminal 
nucleotides. 5’-end amino linker and 3’-end disulfide 
linkers were introduced to the aptamers and STAT3 
sense strand. The gold surface-reactive thiol group 
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reduced from a disulfide bond by DTT or TCEP was 
used for conjugation with AuNP (Figure 1A). As 
expected, AuNP cores were narrowly distributed by 
hydrodynamic diameter (Table 1, Figure 1B). Linker 
sequences composed of the three or six thymidines 
were inserted before the thiol group to enable the 
upright orientation of the ODN strand on AuNP 
surfaces allowing to link more aptamers or STAT3d to 
AuNP because the capacity of binding to the target 
may be compromised otherwise [30]. To ensure that 
fluorescence of NUAP/STAT3d-AuNP is only 
minimally affected by gold surface plasmons and is 
strong enough for cell imaging, amino group on the 
5’-end of ODNs was used for conjugating with Alexa 
Fluor 488, Alexa Fluor 568 (for confocal microscopy) 
or Cy5.5 and 800CW (for NIR imaging) (Figure 1A). 
Amino group was also used to conjugate ODNs with 
MAG3 ligand suitable for radiolabeling with reduced 
[99mTc] pertechnetate in the cell internalization study. 
All six engineered AuNP-NUAP/STAT3d 
nanoconstructs (Table 1 and Table S1) were stable in 
the presence inorganic anions including phosphate 
and could be stored for months at 4oC. The formation 
of aptamer- and STAT3d – linked AuNP-ODNs 
nanoconstructs was analyzed by using 
non-denaturating gel electrophoresis which 
demonstrated the presence of large (non-migrating) 
dual-fluorescence labeled species indicating 
co-localization of the aptamer and the duplex on the 
same AuNP (Figure 1C). The total amount (aptamer 
or STAT3 decoy) bound on AuNP was determined by 
calculating the fluorescence intensity difference 
between the added ODN and free ODN in 
supernatant after AuNP-ODNs purification by 
centrifugation. The amount of ODN (aptamer or 
STAT3 decoy) bound to AuNP varied by the sequence 
and length with shorter ODN having an advantage of 
higher relative content of phosphorothioates in the 
ODNs. AuNP-NUAP had the lowest yield of binding 
to AuNP and resulted in AuNP aggregation because 
NUAP contains a plurality of guanines in the 
sequence. When NUAP and STAT3d were added 
together to AuNP, the yield AuNP-NUAP-STAT3d 
was higher than AuNP-NUAP synthesized by adding 
NUAP only. Hydrodynamic radii and other 
characteristics of AuNP and AuNP-ODN 
nanoconstructs are shown in Table 1. 
Table 1. Characterization of gold nanoparticle-based constructs used in this study. 
Name Diameter by number, nmb Zeta potential, mV AuNP core diameter by 
TEM, nm 
ODN bound to AuNP (% of 
added) c 
ODN/AuNP ratio 
mol/particle  
AuNPa 11.9 -21.7 13.5 ± 1.5 - - 
AuNP-NUAP  - - 2.5 224 
AuNP-CTAP 71.4 -26.8  10.3 84 
AuNP-STAT3d 2.9 -12.9  46.1 101 
AuNP-COTRd 49.4 -28.7  27.7 74 
AuNP-NUAP-STAT3d 18.2 -26.8 17.3 ± 1.4 8.2 NUAP: 49 
STAT3d: 60 
AuNP-CTAP-STAT3d 52.4 -29.5  16.3 CTAP: 38 
STAT3d: 60 
a) AuNP were synthesized as described in [24]; b) hydrodynamic diameters (number average); c) a ratio of [bound ODN]/ [added ODN]*100. 
 
 
Figure 1. A – a scheme showing a gold nanoparticle with cell-surface specific nucleolin aptamer (NUAP) that forms a quadruplex dimer and Alexa Fluor 568 labeled 
STAT3-binding duplex (STAT3d); B – transmission electron microscopy of AuNPs, bar = 100 nm; C- a pseudo-color fluorescent image of a polyacrylamide gel (10% 
TBE) showing electrophoretic analysis of AuNP-ODN constructs and their components, lane: 1) STAT3d; 2) AuNP-STAT3d; 3) AuNP-CTAP-STAT3d; 4) 
AuNP-CTAP; 5) CTAP. Control aptamer CTAP was labeled with Cy5.5 (red) and one of the strands of STAT3d was labeled with NIR Dye 800CW (green). An 
asterisk shows the position of STAT3d-800CW, double asterisk- AuNP conjugates retained at the start; arrow- NUAP-Cy5.5  
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Expression of nucleolin on cell surface of HNC 
cells and STAT3 overexpression 
Because overexpression of nucleolin on HNC 
FaDu cell surface is crucial for cellular uptake and 
trafficking of AuNP-ODN constructs in this study, we 
first tested the levels of nucleolin expression on the 
surface. This was performed by using 
immunofluorescence due to additional expression of 
nucleolin in cytoplasmic and nuclear fraction of cells. 
Human epithelial carcinoma A431 cells were used as 
positive control because they express large amounts 
of nucleolin on the cell surface. NIH-OVCAR3 cell 
line, an ovarian carcinoma cell line with low 
expression of surface nucleolin was used as negative 
control. The total level of nucleolin expression by 
immunofluorescence in the HNC FaDu cell line was 
similar to that of A431 and NIH-OVCAR3 cells 
(Figure 2). However, in both HNC lines nucleolin was 
present in the cytoplasm while in OVCAR cells 
nucleolin was detectable mostly in the nucleoli 
(Figure 2A-C). After subcellular fractionation of FaDu 
and A431 we determined that nucleolin was present 
in the membrane fraction including plasma 
membrane, which was confirmed by Western blotting 
(Figure 2F). We detected both full-length nucleolin 
(106 kDa) and the products of proteolysis [31] in the 
fractions of all cells we tested. Furthermore, we tested 
whether HNC FaDu cells express functional STAT3 
by detecting STAT3 protein by EMSA (Figure 2E) and 
on Western blots (Figure 2F). EMSA showed the 
ability of STAT3d to bind to the protein product 
present in cell lysates after STAT3d was assembled 
from one or two ODNs carrying fluorescent dyes. We 
also found that in protein lysates of FaDu cells the 
levels of expression of STAT3 were similar to the 
levels detected in the positive control, i.e. in HeLa 
cells extract, Figure 2F.  
 
 
Figure 2. Expression of nucleolin (cell-surface target protein) and STAT3 in epithelial cancer cell lines. Immunofluorescence using anti-nucleolin antibody showing 
nucleolin expression in epithelioid carcinoma A431 (A), HNC line FaDu (B); ovarian carcinoma OVCAR3 (C). Secondary FITC-conjugated IgG (green) was used. 
Nuclei were counterstained with DAPI (blue). D- nucleolin expression in membrane (M) and nuclear (N) fractions of cells. Lanes 1,2 - A431, Lanes 3,4 – FaDu, lanes 
5,6- HeLa cells. E- electrophoretic mobility shift assay (EMSA) showing STAT3d alone (lane 1,3) and after adding FaDu cell lysate (lane 2,4). STAT3 d was labeled 
either using Cy5.5 (lanes 1,2) or dual-labeled with Cy5.5 and 800CW(lanes3, 4); F- Western blotting of STAT3 in FaDu cell extract (lane 1) and HeLa extract (lane 
2, positive control). 
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Cytotoxicity of AuNP-ODN nanoconstructs 
Cytotoxicity tests of all synthesized AuNP 
conjugates with ODNs (AuNP-NUAP, AuNP-CTAP, 
AuNP-STAT3d and AuNP-COTRd) were performed 
in FaDu and control non-HNC cells at various 
concentrations. We observed no measureable 
cytotoxicity below 0.1 µM with no significant 
differences between these AuNP constructs and 1 µM 
for aptamers and STAT3 decoys.  
Cell uptake of STAT3d, nucleolin aptamer and 
corresponding AuNP nanoconstructs 
To compare the cell uptake of various AuNP 
nanoconstructs and free aptamers, we conjugated NIR 
dyes 800CW and Cy5.5 to aptamers and STAT3d, 
respectively, which enabled very high sensitivity of 
detection. We investigated whether there were 
measurable differences in the uptake of 
nanoconstructs carrying either nucleolin aptamer 
NUAP or the control aptamer CTAP at four different 
concentrations in cells. Initially we observed that 
independently of cell line free NUAP aptamer 
showed higher binding to the cells than free CTAP 
(Figure 3A). By using the same fluorescent detection 
method we then established that Cy5.5- labeled 
AuNP-NUAP constructs showed about 4-times 
higher cell uptake than AuNP-CTAP constructs in 
both FaDu and A431 cells. By performing cell 
fractionation and measuring fluorescence intensity of 
cell surface and cell-internalized fractions separately 
we determined that on average, more than 90% of the 
AuNP constructs were internalized (Figure 3B). We 
further performed a quantitative comparative uptake 
assay of STAT3d, AuNP-STAT3d and 
AuNP-NUAP-STAT3d which carried one strand of 
STAT3d radiolabeled with [99mTc] (Figure 3C). 
Linking STAT3d to AuNP surface resulted in a strong 
increase of cell uptake of STAT3d: after conjugating 
with AuNP and with nucleolin aptamer-bound AuNP, 
STAT3d uptake increased from 0.12±0.01% to 
3.5±0.51% in A431 cells resulting in approximately a 
30-times increase and from 0.18±0.01% to 1.87±0.27% 
in FaDu cells, i.e. a 10-fold increase. To visualize the 
uptake of AuNP nanoconstructs with confocal 
microscopy, we pre-labeled ODNs with Alexa Fluor 
568 fluorophore before conjugating to the surface of 
AuNP. Figure 4 shows the localization of the 
AuNP-NUAP-STAT3d in the cytoplasm and around 
DAPI-stained nuclei (blue channel) in FaDu and A431 
cell lines. The evidence of the uptake observed by cell 
microscopy was consistent with the results of cell 
lysate NIR fluorescence analysis and measurements of 
radioactivity (Figure 4). The internalization of STAT3 
decoy in cell nuclei as well as in the cytoplasm was 
clearly visible in many A431 and FaDu cells in the 
monolayer culture while no evidence of the uptake 
was observed in the case of free STAT3d. Since we 
additionally stained plasma membrane by using 
anti-EGFR (Cetuximab)- Alexa Fluor 488 conjugate, 
we were able to quantify the Alexa Fluor 568-labeled 
STAT3d in each cell individually. Quantitative 
analysis of optical section volume average intensities 
(expressed in arbitrary units of fluorescence, AU) 
showed that A431 cells were internalizing 
NUAP-targeted AuNP-STAT3d construct more 
efficiently than STAT3d (35.9 AU 
AuNP-NUAP-STAT3d vs. 12.1 AU STAT3d). The 
same trend was observed in the case of FaDu cells: 
30.5 AU AuNP-NUAP-STAT3d vs. 10.4 AU STAT3d 
(Figure 4). 
 
 
Figure 3. The uptake of aptamers and aptamer-linked AuNP nanoconstructs in cell culture. A- Total cell uptake of Cy5.5-labeled nucleolin-specific aptamer (NUAP) 
and control non-specific aptamer (CTAP) incubated with HNC cell line FaDu and squamous carcinoma A431 for 4h. The uptake was determined by using 
measurements of Cy5.5 fluorescence in cell lysates; B- fractional content of surface-bound and internalized AuNP-aptamer-STAT3d constructs in FaDu and A431 
cells. The % of total in the bound and internalized fractions was determined by measuring fluorescence of cell lysates after fractionation (surface and internalized). 
AuNP constructs were incubated in the cell culture for 4h at 37oC. C- Internalization of STAT3d, AuNP-STAT3d and AuNP-NUAP-STAT3d in FaDu and A431 cells 
by [99mTc] radiolabeling of a one of the strand of STAT3d by using modification with MAG3 chelate.  
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Figure 4. Confocal multichannel microscopy of STAT3d and AuNP-NUAP-STAT3d uptake in epithelial cancer cells after incubating with A431 cell culture (A, B) or 
FaDu cells (C, D); AuNP-NUAP-STAT3d (A - A431 cells; C - FaDu cells); STAT3 duplex (B - A431 cells; D - FaDu cells). Blue- DAPI; Green – anti-EGFR-Alexa 
Fluor488 for staining cell plasma membrane; Red – Alexa Fluor 568 (one strand of STAT3 duplex).  
 
Potentiation of STAT3d radiosensitization 
effect 
To investigate whether AuNP-NUAP-STAT3d 
constructs exhibited radiosensitization effect in A431 
and FaDu cells, the cells were subjected to a 
single-dose radiation treatment (RT) in the presence 
or in the absence of STAT3d and 
AuNP-NUAP-STAT3d nanoconstructs after 20h 
incubation. Cetuximab was used as “standard of care” 
therapeutic humanized antibody for head and neck 
cancer treatment. Both viability and the extent of 
genomic DNA damage was assessed by flow 
cytometry. This experiment showed that A431 cells 
were more radiosensitive after treating with 
experimental AuNP-NUAP-STAT3d or STAT3d than 
FaDu cells. The percent of viable A431 cell numbers 
decreased by 20% in STAT3d and 
AuNP-NUAP-STAT3d groups compared to the 
control cells. The degree of cell DNA damage caused 
by constructs showed the following trend in A431 
cells: Cetuximab>AuNP-NUAP-STAT3d>STAT3d. 
Unlike A431, FaDu cells showed high level of 
radioresistance, FaDu cell viability did not change 
after RT was delivered. Among live cell fraction, DNA 
damage measurement (Figure 5B) showed that 
AuNP-NUAP-STAT3d construct, STAT3d and 
Cetuximab caused DNA damage to the cells after 20 h 
incubation. The cell DNA damage levels did not 
change significantly before and after RT for 
Cetuximab group. However, cell DNA damage 
increased almost by 50% after RT in the case of 
AuNP-NU-STAT3d and STAT3d groups. Inhibition of 
STAT3 resulted in radiosensitization of HNC FaDu 
cells. Unlike Cetuximab, STAT3d and 
AuNP-NUAP-STAT3d showed a small but 
statistically significant increase of DNA damage in 
RT-treated FaDu cells (p<0.005). While STAT3d and 
AuNP-NUAP-STAT3d showed similar 
radiosensitization effects in FaDu cells, the actual 
STAT3d concentrations for achieving this effect were 
different with free STAT3d (500 nM) being 4-5 times 
higher than AuNP-NUAP-STAT3d (88 nM STAT3d).  
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Figure 5. The effect of RT on viability (A) of A431 (blue bars) and FaDu cells (red bars) and genomic DNA damage (B) pre- (solid bars) and post- (hatched bars) 
radiation treatment. Both viability and the damage to DNA were determined by using flow cytometry. Control cells (no pre-incubation), or experimental cells 
incubated with 1) Cetuximab (control as a standard immunotherapy for head and neck cancer), 2) STAT3d or 3) AuNP-NUAP-STAT3d for 20h and then either 
mock-irradiated or irradiated with a single dose of 4Gy. Staining performed with FITC- labeled rabbit polyclonal anti- γ-H2AX antibodies and analyzed by FACS. * - 
Indicates statistical significance, p<0.005. 
 
Discussion 
Human head and neck cancers exhibit highly 
malignant phenotypes characterized by the extensive 
invasion into surrounding tissues and metastasis to 
distant organs, even at an early stage [32, 33]. Recent 
studies have identified several promising therapeutic 
targets in HNC [34]. Of these, STAT3 is a leading 
candidate given its increased expression in HNC, 
which promotes tumor metastasis, angiogenesis, 
immune evasion and suppression [35-37]. STAT3 is 
being explored in both pre-clinical models and in 
early clinical trials [38] because of its proven role in 
the pathogenesis and progression of malignant 
tumors [3, 5, 39]. STAT3 decoy oligonucleotide duplex 
specifically binds to activated STAT3 and blocks 
binding of STAT3 to DNA sequences on 
STAT3-responsive promoters, resulting in the 
inhibition of STAT3-mediated transcription, 
potentially inhibiting tumor cell proliferation [2, 40]. 
Since phosphorodiester ODNs are unstable, STAT3d 
must be delivered via local or intratumoral injection. 
To overcome this drawback, phosphorothiates were 
introduced to both termini of STAT3d backbone [41, 
42]. As a consequence, the stability of STAT3d 
increased resulting in extended blood half-life [43-45]. 
AuNPs are also potentially able to increase the 
stability of STAT3d and are capable of high capacity 
delivery of STAT3d into the cells. To increase the 
delivery of nucleolin aptamer or other ODNs such as 
aptamers or siRNA they were linked to AuNP or 
loaded into liposomes. To improve the uptake of 
AuNP nanoconstructs in HNC, we chose to explore 
cell-surface nucleolin aptamer targeting by using an 
AuNP-based delivery system. It has been reported 
that nucleolin aptamer completely inhibited the 
proliferation and exhibited cytotoxicity towards 
MCF-7 cells [46, 47]. Nucleolin aptamer, a 
G-quadruplex oligonucleotide, was shown to have 
high binding affinity to nucleolin with Kd ranging 
from pM to low nM range [48]. It has favorable 
pharmacokinetic properties and a high safety profile 
due to small size, and the absence of immunogenicity 
[23, 46, 49]. Therefore we synthesized 
AuNP-NUAP-STAT3d nanoconstructs with STAT3d 
cargo and nucleolin aptamer appended to the AuNP 
surface to further enhance cancer cell-specific uptake 
of STAT3d under the effect of nucleolin aptamer and 
AuNP. In HNC treatment radiation therapy is 
typically combined with surgical approaches either as 
post-operative adjuvant radiotherapy or as primary 
option in treating laryngeal tumors for organ 
preservation [50]. Since AuNPs are potent 
radiosensitizers [51- 53], AuNP-NUAP-STAT3d has 
the potential to serve as radiosensitizer but the ability 
of nanoconstructs to internalize in cells had to be 
tested. While cytoplasmic localization of AuNP is 
sufficient to yield radiosensitization, nuclear 
penetration enables additional DNA damage via 
physical dose enhancement by the short-range low 
energy electrons (LEEs) and chemical enhancement 
by the very LEEs. The internalization of 
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AuNP-NUAP-STAT3d was critical for our study and 
A431 and FaDu cells were good candidates for 
internalization studies since both cell lines express 
nucleolin on cell surface. By using site-specific [99mTc]- 
labeling of ODN strands with radioisotopes and 
fluorescence intensity measurements we showed that 
AuNP-NUAP-STAT3d is capable to internalize in 
HNC FaDu cells. Nucleolin aptamer of AuNP 
nanoconstruct assisted in the internalization of 
AuNP-NUAP-STAT3d. This result is consistent with 
published data that showed dense packing of NUAP 
on AuNP favoring the internalization of 
NUAP-AuNP in a wide range of cancer cells [54]. In 
our study, AuNP-NUAP-STAT3d were able to deliver 
almost 30 times more STAT3d than STAT3d alone to 
A431 cells and 10 times more into FaDu cells. It is 
important to note that it is more practical to utilize 
NUAP as a cell-specific targeting agent rather than 
therapeutic agent because the required quantity of 
NUAP is much lower. It has been previously 
established that STAT3 inhibition resulted in potential 
increase of radiosensitivity in HNC either by using 
small molecule inhibitors, small interfering RNA 
(siRNA) or short hairpin RNA (shRNA) [36, 37, 55, 
56]. Our results suggest that radiosensitization effect 
of STAT3d can also be enhanced by gold 
nanoparticles, which likely induce apoptosis via 
enhanced DNA double-strand break formation.  
In conclusion, we demonstrated that 1) both 
STAT3d duplex and STAT3d-linked to 
nucleolin-targeted AuNPs nanoconstructs show 
similar decrease of viability in A431 cells (20%) after 
receiving irradiation, 2) they result in 
radiosensitization effect in radioresistant FaDu cells. 
The linking of STAT3d duplex to AuNP-NUAP 
resulted in a more efficient STAT3d internalization in 
cells than STAT3d alone. The improved 
internalization of AuNP-NUAP nanoconstructs and 
the presence of AuNP cores were both contributing to 
the amplification of STAT3d effect in FaDu cells 
which was observed at a 4-times lower concentration 
of STAT3d (as a component of AuNP-NUAP-STAT3d, 
88 nM) than in the case of STAT3d alone (500 nM).  
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